Double Medical Technology Inc.
SZSE:002901.SZ
33.24 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,135.559 | 1,533.121 | 1,434.099 | 1,994.334 | 1,586.86 | 1,257.318 | 772.47 | 594.015 | 462.664 | 391.825 | 298.892 | 202.655 |
| Cost of Revenue
| 667.258 | 527.793 | 333.92 | 311.056 | 224.231 | 180.922 | 151.432 | 100.602 | 83.464 | 74.318 | 59.431 | 41.982 |
| Gross Profit
| 1,468.301 | 1,005.328 | 1,100.179 | 1,683.278 | 1,362.63 | 1,076.396 | 621.037 | 493.413 | 379.199 | 317.507 | 239.46 | 160.672 |
| Gross Profit Ratio
| 0.688 | 0.656 | 0.767 | 0.844 | 0.859 | 0.856 | 0.804 | 0.831 | 0.82 | 0.81 | 0.801 | 0.793 |
| Reseach & Development Expenses
| 293.908 | 285.276 | 256.717 | 167.067 | 128.024 | 100.377 | 64.81 | 53.662 | 39.959 | 35.783 | 23.798 | 0 |
| General & Administrative Expenses
| 36.664 | 31.535 | 38.931 | 23.189 | 16.467 | 14.203 | 12.746 | 9.167 | 14.721 | 10.725 | 6.029 | 29.107 |
| Selling & Marketing Expenses
| 378.697 | 365.717 | 662.895 | 655.18 | 502.492 | 409.849 | 120.949 | 72.201 | 52.966 | 41.739 | 28.157 | 20.341 |
| SG&A
| 415.361 | 665.537 | 701.826 | 678.369 | 518.959 | 424.053 | 133.694 | 81.369 | 67.687 | 52.464 | 34.186 | 49.448 |
| Other Expenses
| 329.476 | -43.877 | 25.672 | 19.842 | 6.92 | 0.1 | -0.084 | -0.595 | 18.597 | 9.918 | 7.086 | 5.643 |
| Operating Expenses
| 1,038.745 | 937.646 | 984.215 | 865.278 | 653.902 | 524.53 | 208.14 | 139.974 | 138.918 | 110.059 | 75.409 | 52.842 |
| Operating Income
| 429.556 | 103.216 | 147.452 | 822.007 | 714.74 | 571 | 440.786 | 350.929 | 242.982 | 213.915 | 159.682 | 108.891 |
| Operating Income Ratio
| 0.201 | 0.067 | 0.103 | 0.412 | 0.45 | 0.454 | 0.571 | 0.591 | 0.525 | 0.546 | 0.534 | 0.537 |
| Total Other Income Expenses Net
| -1.142 | -3.476 | 0.127 | -19.495 | -5.107 | -2.024 | -0.084 | -0.595 | 18.455 | 9.894 | 6.684 | 5.643 |
| Income Before Tax
| 428.414 | 99.741 | 147.459 | 802.512 | 709.633 | 568.976 | 440.702 | 350.333 | 261.52 | 223.81 | 166.366 | 114.533 |
| Income Before Tax Ratio
| 0.201 | 0.065 | 0.103 | 0.402 | 0.447 | 0.453 | 0.571 | 0.59 | 0.565 | 0.571 | 0.557 | 0.565 |
| Income Tax Expense
| 43.122 | 13.405 | 38.228 | 111.012 | 94.879 | 90.271 | 62.617 | 49.737 | 39.592 | 35.107 | 28.151 | 17.93 |
| Net Income
| 356.803 | 58.972 | 92.555 | 673.309 | 605.684 | 465.491 | 371.453 | 295.556 | 219.328 | 188.507 | 139.29 | 96.812 |
| Net Income Ratio
| 0.167 | 0.038 | 0.065 | 0.338 | 0.382 | 0.37 | 0.481 | 0.498 | 0.474 | 0.481 | 0.466 | 0.478 |
| EPS
| 0.86 | 0.14 | 0.22 | 1.68 | 1.51 | 1.16 | 0.93 | 0.8 | 0.61 | 0.59 | 2.68 | 0.3 |
| EPS Diluted
| 0.86 | 0.14 | 0.22 | 1.67 | 1.51 | 1.16 | 0.93 | 0.8 | 0.61 | 0.59 | 2.68 | 0.3 |
| EBITDA
| 560.509 | 218.775 | 246.066 | 873.915 | 759.057 | 591.653 | 441.534 | 375.585 | 287.531 | 237.709 | 180.056 | 107.337 |
| EBITDA Ratio
| 0.262 | 0.143 | 0.172 | 0.438 | 0.478 | 0.471 | 0.572 | 0.632 | 0.621 | 0.607 | 0.602 | 0.53 |